Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102250005A details a novel chiral catalytic hydrogenation route for Eslicarbazepine, offering superior atom economy and simplified purification for API manufacturing.
Patent CN111056932A reveals a high-efficiency rhodium-catalyzed asymmetric hydrogenation process. Achieve superior turnover numbers and purity for industrial scale-up.
Patent CN101400632A details novel Ruthenium-P-N complexes for high-ee ketone hydrogenation, offering cost reduction in API manufacturing and reliable supply chain solutions.
Advanced patent CN102633664A details a low-pressure Ruthenium-catalyzed route for high-purity L-carnitine, offering significant cost reduction and supply chain reliability for global manufacturers.
Patent CN117362359A reveals record-breaking asymmetric hydrogenation technology. Achieve superior purity and cost efficiency in pharmaceutical intermediate manufacturing.
Patent CN111057729A details a green enzymatic route for Larotretinib intermediates, offering high ee values and cost reduction in API manufacturing.
Patent CN106938995B details asymmetric synthesis for bepotastine besilate. This method offers significant cost reduction and supply chain reliability for ophthalmic drug intermediate manufacturing partners.
Patent CN115340572B discloses X-Binaphane, a novel xanthene-based bisphosphine ligand enabling high stereoselectivity in API manufacturing with scalable synthesis.
Patent CN105585516B reveals advanced palladium catalysis for high-purity pharmaceutical intermediates. Achieve substantial cost reduction and supply chain reliability.
Patent CN1166672C details a novel Ru-H4-BINAP-diamine complex for asymmetric hydrogenation, offering high enantioselectivity and cost-effective manufacturing for chiral alcohol intermediates.
Advanced process for 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one using Mg-Reformatsky and Ru-catalysis. Delivers cost reduction in pharmaceutical intermediate manufacturing.
Patent CN1139576C details a novel iridium-catalyzed asymmetric hydrogenation process for producing high-purity dextromethorphan intermediates with enhanced supply chain reliability.
Novel rhodium-catalyzed route for indaziflam intermediate offers high ee value and industrial scalability for agrochemical supply chains.
Novel asymmetric hydrogenation ligand CN120484023A ensures high ee and scalable production for pharmaceutical intermediates manufacturing supply chains.
Patent CN110526944A reveals high-efficiency Ru catalyst for asymmetric transfer hydrogenation, offering cost reduction and supply reliability.
Patent CN114644614B details a novel 3-step synthesis for L-nicotine achieving >99.9% optical purity. Discover cost-effective, scalable manufacturing solutions for pharmaceutical intermediates.
Patent CN114644614B reveals a novel 3-step route to L-nicotine with >99.9% ee. Discover cost-effective manufacturing and supply chain advantages for pharma intermediates.
Novel ferrocene-based PNO ligand patent CN113004341B enables high-selectivity asymmetric hydrogenation for cost-effective pharmaceutical intermediate manufacturing and supply chain stability.
Patent CN1566084A reveals novel water-soluble diamines enabling green asymmetric hydrogenation. Discover cost-effective API intermediate manufacturing solutions.
Patent CN101346352B reveals efficient Rh-catalyzed asymmetric reduction for Mitiglinide. Offers high optical purity and industrial scalability for diabetes drug intermediates.